U.S., March 10 -- ClinicalTrials.gov registry received information related to the study (NCT07457190) titled 'Pharmacokinetic Study of Buagafuran Capsules in Participants With Hepatic Impairment and Normal Hepatic Function' on Feb. 26.
Brief Summary: This study adopts a non-randomized, open label, parallel, single-dose design to evaluate the safety and pharmacokinetic characteristics of Buagafuran capsules in participants with hepatic impairment.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Generalized Anxiety Disorder
Intervention:
DRUG: Buagafuran
participants to receive Buagafuran capsules 30 mg on an empty stomach on the morning of Day1
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Beijing Union Pharma...